Immunotherapy in Urological Tumors

Reviews in Urology

An¹  Sharma²  Narin Suleyman³ 

[1] Department of Oncology, Mount Vernon Cancer Centre, Northwood, UK;Hertfordshire and Bedfordshire Urological Cancer Centre and Department of Urology and Surgery, Lister Hospital, East and North Herts NHS Trust, Stevenage, UK;School of Life and Medicine Sciences, University of Hertfordshire, Hatfield, UK

关键词: Immunotherapy;    Urological tumors;    Immune checkpoint inhibitors;    Recombinant BCG;    Cell wall-derived therapies;    Cytokines;   

DOI  :  

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

The past decade has seen significant improvement in our understanding of tumor biological features, which has led to use of anti-programmed-death 1 (PD-1) and anti-PD-ligand-1 (PD-L1) agents and cytotoxic T lymphocytes antigen 4 (CTLA-4) inhibitors in a multitude of cancers. These immunotherapeutic agents have shown activity in melanoma, lung, head and neck, colorectal, urological, and other cancers. This article details the use of immunotherapy agents in urothelial, renal, prostate, and testicular tumors.

【 授权许可】

Unknown